Biogen's Diranersen Drug Shows Promise in Slowing Alzheimer's Progression
724FinanceDr. Yaman Ege
Key Highlights
Biogen'in diranersen adlı deneysel Alzheimer ilacının ilk klinik test sonuçları ortaya çıktı. Çoklu skleroz hastalarına uygulanan ilaç, hastaların bil
Initial clinical trial results for Biogen's experimental Alzheimer's drug, diranersen, have shown promising results. When administered to multiple sclerosis patients, the drug slowed cognitive decline by 30%. This suggests potential for early-stage Alzheimer's prevention. The experimental medication reduced amyloid plaque formation, allowing brain cells to function more efficiently. Biogen plans to advance diranersen to broader clinical trials. The development could mark a significant breakthrough in Alzheimer's treatment.
Related News & Analysis
View All →
Trump's Debt and Inflation Quagmire: Market Implications Ahead of the Midterms
Jim Cramer Predicts Substantial Upside for Jersey Mike’s Subs Stock
Mattel Accelerates KPop Demon Hunters Toy Line, Tapping Global Streaming Success
UK Faces AI‑Traffic Crunch Without Faster 5G Rollout
Brave Gains Edge Over Chrome with New Email Alias Feature
Trump Announces Strategic Partnership for Vast Venezuelan Oil Reserves
Latest Market News
All News →
Norway’s 20-Unit Patria Armored Vehicle Order Signals a Shift in Northern European Defense Economics
ADRA GAYRIMENKUL YATIRIM PARTNERSHIP: Turkey's Dual-Faceted Investment Strategy
S&P 500 Climbs Amid AI Frenzy: How Big Tech Titans Shape the Index
ECB's Middle East Resilience Paves Way for September Rate Hike
Trump's Debt and Inflation Quagmire: Market Implications Ahead of the Midterms